Navigation Links
Dalton Pharma Services and ProCitius Announce a Strategic Alliance to Provide Contract Chemistry Services
Date:5/11/2009

TORONTO, and CHENNAI, India, May 11 /PRNewswire/ -- Dalton Pharma Services and ProCitius Research jointly announce a strategic alliance created to provide clients with contract chemistry services of exceptional value.

Global pharmaceutical companies, in order to maintain their discovery and development output in an era of severe cost restraints, have been increasing their use of "offshore" contract research organizations (CROs) in countries such as China and India. Despite the quality of chemists in offshore CROs, there are often performance issues caused by communication and cultural differences. In order to ensure quality and timeliness in the contracted work, pharmaceutical companies are usually forced to dedicate senior staff to manage these projects on-site or from Western research centers.

Dalton and ProCitius have teamed up to offer clients the best of both worlds. Projects carried out by ProCitius in India are tightly controlled by senior Dalton project managers based at the company headquarters in Canada. Clients deal only with Dalton, which assumes full legal and operational responsibility for the satisfactory execution of the contract. The contract pricing is based on attractive FTE rates.

"I believe this type of hybrid service fills an important need in our industry," said Peter Pekos, President and CEO of Dalton Pharma Services. "Over the past two decades I have worked to adjust our service offering to meet the changing requirements of my clients and today's announcement is part of this continuing evolution," he continued. "In ProCitius we have the ideal partner: well-established; large FTE headcount; excellent facilities and infrastructure; robust documentation; and a reputation for high ethical and environmental standards."


'/>"/>
SOURCE Dalton Pharma Services
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. BioRelix and Dalton Medicinal Chemistry Expand and Renew Research Agreement to Capitalize on Riboswitches
2. Dalton Pharma Services Licenses Thermo Fisher Scientific Technology to Produce Polynucleotides for Drug Development
3. BIKAM and Dalton Medicinal Chemistry Sign Collaborative Research Agreement
4. Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
5. BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology
6. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
7. Pharmaceutical Packaging Equipment Manufacturer Boosts European Distribution
8. PharmAthene Announces New Date for First Quarter 2009 Conference Call and Webcast
9. Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
10. PDL BioPharma Announces First Quarter 2009 Financial Results
11. Rib-X Pharmaceuticals Announces Presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... , DALLAS, Dec. 3 ...rd: ACCP), today provided an update on its Europea...atment for oral mucositis, a debilitating side eff...d is commercially launched by Access, partner, Spe..., Germany, Italy, Norway, Greece and Sweden. Acces...
(Date:12/3/2009)..., TUSTIN, Calif., Dec. 3 /PRNewswire-FirstCall/... ) today announced that it will release its financ...2010 on December 10, 2009 at 7:00 a.m. EST and wil...e results at 11:30 a.m. EST on the same day. ,,...ial results for the second quarter ended October 3...
(Date:12/3/2009)... , NEW DELHI, India, Dec. 3 /PRNewswire-...ce Officer at Shenzhen Beike Biotechnology Co. Ltd...ference on High-Risk Diabetic,Foot Care in New Del...ding,stem cell research and regenerative medicine ...he Indian Podiatry Association (IPA), aimed,to hel...
(Date:12/2/2009)... , NEW YORK, Dec. 2 Reportlink... is available in its catalogue: ,, Neurostimul.../www.reportlinker.com/p0164232/Neurostimulation---... neurostimulation market stands enthused by the gr...rise in age-related diseases such as, Parkinson,s,...
Breaking Biology Technology:Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Neurostimulation - A Global Market Perspective 2Reportlinker Adds Neurostimulation - A Global Market Perspective 3Reportlinker Adds Neurostimulation - A Global Market Perspective 4Reportlinker Adds Neurostimulation - A Global Market Perspective 5Reportlinker Adds Neurostimulation - A Global Market Perspective 6
...c. (NYSE Alternext US: IMM.BC) today announced tha...ding (MOU) confirming its interest in exploring th... Pharmaceutical Group Co. Ltd. (BPGC). The MOU co...f collaborative global business development opport...est state-owned pharmaceutical and medical device ...
... million in Q4 2007 - a 4.0% increase , , Q4 200...n Q4 2007 - a 10.0% increase , , Q4 2008 New Book... - a 15.1% increase , , 2008 Net Revenues -- $133...rease , , 2008 Diluted Net Income per Share of $0... New Bookings of $187.2 million vs. $138.6 million...
... (NYSE: LMT ) has partnered with Penn State Uni...nergy sector. As part of the corporation,s commitm...s, Lockheed Martin will fund $400,000 of research ..., , Leveraging a partnership spanning more than 3... collaboration will focus on Smart Grid technolog...
Other Biology Technology:Immtech and Beijing Pharmaceutical Group Co. Sign Memorandum of Understanding to Explore Developing Strategic Business Alliance 2Immtech and Beijing Pharmaceutical Group Co. Sign Memorandum of Understanding to Explore Developing Strategic Business Alliance 3ERT Reports Fourth Quarter and Full Year 2008 Results 2ERT Reports Fourth Quarter and Full Year 2008 Results 3ERT Reports Fourth Quarter and Full Year 2008 Results 4ERT Reports Fourth Quarter and Full Year 2008 Results 5ERT Reports Fourth Quarter and Full Year 2008 Results 6ERT Reports Fourth Quarter and Full Year 2008 Results 7ERT Reports Fourth Quarter and Full Year 2008 Results 8ERT Reports Fourth Quarter and Full Year 2008 Results 9ERT Reports Fourth Quarter and Full Year 2008 Results 10ERT Reports Fourth Quarter and Full Year 2008 Results 11Lockheed Martin Invests in Smart Grid Research and Development at Penn State University 2
(Date:12/2/2009)...ple who smoke their first cigarette within minutes...ne, a by-product of nicotine when processed by the... the number of cigarettes smoked. , "Since co...ancer, our results suggest that smokers who smoke ... for lung cancer," said researcher Joshua E. Musca...
(Date:12/2/2009)...osure to secondhand smoke for a prolonged period o...of breast cancer, even in women who never smoked c...r exposure to side-stream smoke could increase ris...d Peggy Reynolds, Ph.D., senior research scientist...ey office. "While no single epidemiologic study ca...
(Date:12/2/2009)...╤ A Smoky Mountain forest,s woodland herb po... how forest understories recover from logging, acc...heavy logging in portions of the forest nearly 80 ...the secondary forest floor was similar to that of ...tant professor of forestry and natural resources, ...
Breaking Biology News(10 mins):Increased nicotine levels detected in those who light-up earlier 2Exposure to secondhand cigarette smoke over a lifetime increased breast cancer risk later in life 2Study finds logging effects vary based on a forest's history, climate 2Oxygen Biotherapeutics Inc Announces Closing of Offer to Acquire Warrants 52154 1Oxygen Biotherapeutics Inc Announces Closing of Offer to Acquire Warrants 52154 2Oxygen Biotherapeutics Inc Announces Closing of Offer to Acquire Warrants 52154 3NewLink Genetics Corporation Closes 247 5 Million Financing 13102 1OncoGenex Pharmaceuticals to Raise 249 5 Million Through Sale of Common Stock 13100 1OncoGenex Pharmaceuticals to Raise 249 5 Million Through Sale of Common Stock 13100 2OncoGenex Pharmaceuticals to Raise 249 5 Million Through Sale of Common Stock 13100 3
...al/ethnic groups examined, Hispanic women were fou...sociated gene mutation BRCA1 at 3.5 percent, with ...percent), according to a study in the December 26 ...or gene BRCA1 confer high risks of breast and ovar...s has been estimated at 65 percent for breast canc...
...from their leaves to flowers, roots, fruits and ot...ering techniques, Cornell researchers have finally..., The findings not only deepen understanding of ba...ers to genetically engineer plants with increased ...take. This might be critically important in an era...
...iety has announced the winners of its internationa... Biophysical Society and the International Biophys...-6, 2008. The purpose of these awards is to foste...n biophysicists and scientists working in countrie... of this competitive award are chosen based on sci...
Other Biology News:Varying prevalence among ethnic groups of gene mutation that increases risk of breast cancer 2Varying prevalence among ethnic groups of gene mutation that increases risk of breast cancer 3Cornell researchers prove how plants transport sugars 2Biophysical Society announces 2008 International Travel Awards 2Biophysical Society announces 2008 International Travel Awards 3Biophysical Society announces 2008 International Travel Awards 4Biophysical Society announces 2008 International Travel Awards 5Biophysical Society announces 2008 International Travel Awards 6Biophysical Society announces 2008 International Travel Awards 7
...roarray is specifically designed for location anal... by pairing chromatin immunoprecipitation (ChIP) w...ust hybridization and reliable binding data with g...es. In addition, Agilent provides flexibility by o...
...Microarray is specifically designed for location a...y pairing chromatin immunoprecipitation (ChIP) wit...t hybridization and reliable binding data with gre.... In addition, Agilent provides flexibility by off...
...ation of the budding yeast, Saccharoyces sp.. The ...ly by mixing a plasmid DNA and the kit reagents wi...h as centrifugation or cell washing, are required....ughput transformation of a large number of yeast s...
...ased research with S. aureus, Sigma-Genosys has de...contains PCR primers to amplify all open reading f...er pairs are included to amplify ORFs that are uni.... The ORFmer set contains primers to amplify all 2...
Biology Products: